Treatment of H. pylori Infection After Bismuth Quadruple Therapy Failure

Introduction to Second-Line Therapy

The American College of Gastroenterology recommends levofloxacin-based triple therapy as the preferred second-line option after bismuth quadruple therapy failure, with a regimen consisting of levofloxacin 500mg once daily, a proton pump inhibitor (PPI) twice daily, and clarithromycin 500mg twice daily for 14 days, in patients with a confirmed penicillin allergy 1, 2, 4
The Toronto, Maastricht V/Florence, and American College of Gastroenterology guidelines recommend levofloxacin-based therapy as the preferred second-line option after bismuth quadruple therapy failure, avoiding re-exposure to metronidazole and tetracycline 1, 2

The American Gastroenterological Association strongly advises against using levofloxacin in patients with chronic bronchopneumopathy or prior fluoroquinolone exposure, due to high likelihood of resistance 5
The European Helicobacter Study Group recommends susceptibility testing before prescribing levofloxacin due to rapidly rising resistance rates globally, with consideration of alternative therapies if resistance is suspected 2, 5

The American College of Gastroenterology suggests clarithromycin-based triple therapy (PPI, clarithromycin, metronidazole) as an alternative option if levofloxacin is contraindicated or resistance is documented, but only in areas with low clarithromycin resistance (<15%) 1, 5
The Toronto consensus guidelines recommend rifabutin-based triple therapy (rifabutin 150-300mg daily, clarithromycin 500mg twice daily, PPI twice daily for 10 days) as a third-line therapy option, with monitoring for myelotoxicity risk 1, 3, 4

The American College of Gastroenterology recommends using high-dose PPI twice daily (double the standard dose) to improve eradication rates 4
The Maastricht V/Florence consensus guidelines advise ensuring a 14-day duration of therapy, rather than shorter courses, to significantly improve eradication rates 1, 4

The European Helicobacter Study Group warns against reusing clarithromycin or levofloxacin after initial failure, as resistance develops rapidly after exposure 2
The American Gastroenterological Association advises against using 7-day or 10-day regimens, as 14 days is required for optimal eradication in salvage therapy 1, 4